Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 8315454, 9 pages
http://dx.doi.org/10.1155/2016/8315454
Research Article

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

1Department of Geriatrics, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China
2Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China
3Shanghai Key Laboratory of Diabetes Mellitus, 600 Yishan Road, Shanghai 200233, China
4Shanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China

Received 6 November 2014; Revised 2 June 2015; Accepted 1 July 2015

Academic Editor: Afshan Malik

Copyright © 2016 Yun-Xia Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Park, W. K. Jeon, S. H. Kim et al., “Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, part 1, pp. 138–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. C. Farrell, “Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?” Journal of Gastroenterology and Hepatology, vol. 18, no. 2, pp. 124–138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Chitturi, G. C. Farrell, and J. George, “Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?” Journal of Gastroenterology and Hepatology, vol. 19, no. 4, pp. 368–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Targher, J. Kendrick, G. Smits, and M. Chonchol, “Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 8, pp. 583–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Yang, Y. Ding, Y. Chen et al., “The proteomics of lipid droplets: structure, dynamics, and functions of the organelle conserved from bacteria to humans,” Journal of Lipid Research, vol. 53, no. 7, pp. 1245–1253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. A. Brown, “Lipid droplets: proteins floating on a pool of fat,” Current Biology, vol. 11, no. 11, pp. R446–R449, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Okumura, “Role of lipid droplet proteins in liver steatosis,” Journal of Physiology and Biochemistry, vol. 67, no. 4, pp. 629–636, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Matsusue, T. Kusakabe, T. Noguchi et al., “Hepatic steatosis in leptin-deficient mice is promoted by the PPARγ target gene Fsp27,” Cell Metabolism, vol. 7, no. 4, pp. 302–311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Li, Y. Song, L.-J. Zhang et al., “LSDP5 enhances triglyceride storage in hepatocytes by influencing lipolysis and fatty acid β-oxidation of lipid droplets,” PLoS ONE, vol. 7, no. 6, Article ID e36712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Y. Toh, J. Gong, G. Du et al., “Up-regulation of mitochondrial activity and acquirement of brown adipose tissue-like property in the white adipose tissue of Fsp27 deficient mice,” PLoS ONE, vol. 3, no. 8, Article ID e2890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Matsusue, “A physiological role for fat specific protein 27/cell death-inducing DFF45-like effector C in adipose and liver,” Biological and Pharmaceutical Bulletin, vol. 33, no. 3, pp. 346–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. N. E. Wolins, B. K. Quaynor, J. R. Skinner et al., “OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization,” Diabetes, vol. 55, no. 12, pp. 3418–3428, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Hsiao, J. Chapman, J. M. Ofrecio et al., “Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats,” The American Journal of Physiology - Endocrinology and Metabolism, vol. 300, no. 1, pp. E164–E174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bijland, E. J. Pieterman, A. C. E. Maas et al., “Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE3-Leiden.CETP mice,” The Journal of Biological Chemistry, vol. 285, no. 33, pp. 25168–25175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Gong, Z. Sun, and P. Li, “CIDE proteins and metabolic disorders,” Current Opinion in Lipidology, vol. 20, no. 2, pp. 121–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Magnusson, A. Gummesson, C. A. M. Glad et al., “Cell death-inducing DFF45-like effector C is reduced by caloric restriction and regulates adipocyte lipid metabolism,” Metabolism, vol. 57, no. 9, pp. 1307–1313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Hall, E. M. Brunt, S. Klein, and B. N. Finck, “Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss,” Obesity, vol. 18, no. 2, pp. 417–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Xu, J. G. Park, J. S. So, and A. H. Lee, “Transcriptional activation of Fsp27 by the liver-enriched transcription factor CREBH promotes lipid droplet growth and hepatic steatosis,” Hepatology, vol. 61, no. 3, pp. 857–869, 2015. View at Publisher · View at Google Scholar
  19. D. Aibara, K. Matsusue, K. Matsuo, S. Takiguchi, F. J. Gonzalez, and S. Yamano, “Expression of hepatic fat-specific protein 27 depends on the specific etiology of fatty liver,” Biological and Pharmaceutical Bulletin, vol. 36, no. 11, pp. 1766–1772, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Bedoucha, E. Atzpodien, and U. A. Boelsterli, “Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones,” Journal of Hepatology, vol. 35, no. 1, pp. 17–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Memon, L. H. Tecott, K. Nonogaki et al., “Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice,” Endocrinology, vol. 141, no. 11, pp. 4021–4031, 2000. View at Google Scholar · View at Scopus
  22. K. Matsusue, M. Haluzik, G. Lambert et al., “Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 737–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Morán-Salvador, M. López-Parra, V. García-Alonso et al., “Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts,” The FASEB Journal, vol. 25, no. 8, pp. 2538–2550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. U. A. Boelsterli and M. Bedoucha, “Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes,” Biochemical Pharmacology, vol. 63, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Satoh, N. Ide, Y. Kagawa, and T. Maeda, “Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice,” Biological and Pharmaceutical Bulletin, vol. 36, no. 4, pp. 616–623, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Moreno, A. Lombardi, E. Silvestri et al., “PPARs: nuclear receptors controlled by, and controlling, nutrient handling through nuclear and cytosolic signaling,” PPAR Research, vol. 2010, Article ID 435689, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Yu, K. Matsusue, P. Kashireddy et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. I. A. Leclercq, V. A. Lebrun, P. Stärkel, and Y. J. Horsmans, “Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone,” Laboratory Investigation, vol. 87, no. 1, pp. 56–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Razavizade, R. Jamali, A. Arj, S. M. Matini, A. Moraveji, and E. Taherkhani, “The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial,” Hepatitis Monthly, vol. 13, no. 5, Article ID e9270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Perreault, B. C. Bergman, D. M. Hunerdosse, D. J. Howard, and R. H. Eckel, “Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans,” Metabolism: Clinical and Experimental, vol. 60, no. 8, pp. 1107–1114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Ueno, Y. Saitoh, M. Mizuta et al., “Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome,” Obesity Research and Clinical Practice, vol. 5, no. 4, pp. e335–e340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. E. H. Koh, M. S. Kim, J. Y. Park et al., “Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation,” Diabetes, vol. 52, no. 9, pp. 2331–2337, 2003. View at Google Scholar
  34. M. S. Kostapanos, A. Kei, and M. S. Elisaf, “Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease,” World Journal of Hepatology, vol. 5, no. 9, pp. 470–478, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Z. Hong, L. D. Li, and L. M. Wu, “Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 1-2, pp. 27–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Shiri-Sverdlov, K. Wouters, P. J. V. Gorp et al., “Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates,” Journal of Hepatology, vol. 44, no. 4, pp. 732–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. C. L. Gentile, D. Wang, K. T. Pfaffenbach, R. Cox, Y. Wei, and M. J. Pagliassotti, “Fatty acids regulate CREBh via transcriptional mechanisms that are dependent on proteasome activity and insulin,” Molecular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 99–107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Kim, R. Mendez, Z. Zheng et al., “Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21,” Endocrinology, vol. 155, no. 3, pp. 769–782, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Zhang, G. Wang, Z. Zheng et al., “Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice,” Hepatology, vol. 55, no. 4, pp. 1070–1082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. K. T. Dalen, T. Dahl, E. Holter et al., “LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 2, pp. 210–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and T. Osumi, “MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor α,” Journal of Biological Chemistry, vol. 281, no. 20, pp. 14232–14240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Grasselli, A. Voci, I. Demori et al., “3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver,” Journal of Endocrinology, vol. 212, no. 2, pp. 149–158, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Hall, E. M. Brunt, Z. Chen et al., “Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice,” Journal of Lipid Research, vol. 51, no. 3, pp. 554–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. G. Granneman, H.-P. H. Moore, E. P. Mottillo, Z. Zhu, and L. Zhou, “Interactions of perilipin-5 (Plin5) with adipose triglyceride lipase,” The Journal of Biological Chemistry, vol. 286, no. 7, pp. 5126–5135, 2011. View at Publisher · View at Google Scholar · View at Scopus